Massive taiwan study reveals COVID-19 impact and treatment insights
NCT ID NCT06085924
First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 23 times
Summary
This study used health records from over 8 million people in Taiwan to understand the effects of COVID-19 and how well the oral treatment nirmatrelvir/ritonavir (Paxlovid) worked. Researchers looked at who got severely ill, needed hospital care, or died, and compared those who took the treatment with those who did not. The goal was to learn more about the disease and the real-world use of the medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Taiwan
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.